Global CMO/CDMO Market By Product Type, By Therapeutic Area, By End Use Industry, By Region & Segmental Insights Trends and Forecast, 2024 – 2034

  • Industry: Healthcare
  • Report ID: TNR-110-1059
  • Number of Pages: 420
  • Table/Charts : Yes
  • March, 2024
  • Base Year : 2024
  • No. of Companies : 10+
  • No. of Countries : 29
  • Views : 10052
  • Covid Impact Covered: Yes
  • War Impact Covered: Yes
  • Formats : PDF, Excel, PPT

Contract Manufacturing Organization (CMO) and Contract Development and Manufacturing Organization (CDMO) market play pivotal roles in the pharmaceutical, biotechnology, and healthcare industries. These organizations offer a range of services, from drug development and formulation to manufacturing and packaging. The market has witnessed significant growth due to several factors, including increasing outsourcing trends by pharmaceutical companies, cost-saving initiatives, and the complexity of drug development processes.

CMOs/CDMOs provide flexibility, expertise, and specialized infrastructure, allowing pharmaceutical companies to focus on core competencies such as research and marketing. Moreover, the expanding biopharmaceutical sector, coupled with the demand for personalized medicines, has further fuelled the market’s growth. In terms of revenue, the global CMO/CDMO market was worth US$ 21.2 Bn in 2023 and is anticipated to witness a CAGR of 6.5% during 2024 – 2034.

Global CMO/CDMO Market Revenue & Forecast, (US$ Million), 2016 – 2034

Trends in the Global CMO/CDMO Market

  • A notable trend in the global CMO/CDMO market is the increasing focus on personalized medicine. With advancements in genomics and targeted therapies, pharmaceutical companies are seeking CMOs/CDMOs capable of delivering tailored drug development and manufacturing solutions. This trend reflects the shift towards individualized treatments, driving demand for flexible manufacturing processes and technologies that can accommodate small batch sizes and rapid scale-up capabilities.
  • Pharmaceutical companies are outsourcing tasks such as nanomedicines, lipid-based formulations, and controlled-release formulations to leverage the specialized expertise and infrastructure offered by CMOs/CDMOs. This trend allows pharmaceutical companies to access advanced technologies and reduce time-to-market for innovative drug products while mitigating the risks associated with in-house development of complex formulations.

Manufacturing services type dominated the global market during the forecast period. Pharmaceutical companies increasingly outsource manufacturing activities to CMOs/CDMOs to capitalize on their specialized expertise and infrastructure, allowing them to focus on core competencies like research and development.

Additionally, the growing complexity of drug manufacturing processes, particularly for biologics and advanced therapies, necessitates the involvement of CMOs/CDMOs with advanced technologies and regulatory compliance. Also, the cost-effectiveness and scalability offered by outsourcing manufacturing services contribute to the preference for CMO/CDMO partnerships. As a result, drug substance manufacturing is expected to remain the dominant segment in the CMO/CDMO market, driving its growth during the forecast period.

By therapeutic area, the infectious diseases segment gained popularity in recent years and is anticipated to grow the fastest over the forecast timeline. The emergence of new infectious pathogens and the re-emergence of previously controlled diseases have heightened global awareness and investment in combating infectious diseases. Events such as the COVID-19 pandemic have underscored the critical need for rapid response capabilities, leading to increased demand for contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) specializing in infectious disease therapeutics.

Moreover, advancements in biotechnology and molecular biology have facilitated the development of novel therapeutics and vaccines targeting infectious agents. This has spurred pharmaceutical companies and biotech’s to outsource manufacturing processes to specialized CMOs/CDMOs with the requisite expertise and infrastructure.

The pharmaceuticals segment by end use industry accounted for the largest revenue share in 2023 in the global market. The increasing complexity of drug development processes, coupled with stringent regulatory requirements, has led pharmaceutical companies to seek specialized expertise and infrastructure offered by CMOs/CDMOs. Additionally, the rising demand for personalized medicine and biologics has fuelled the need for flexible manufacturing capacities provided by outsourcing partners.

Furthermore, cost-saving strategies, operational efficiencies, and focus on core competencies have incentivized pharmaceutical companies to collaborate with CMOs/CDMOs for various stages of drug development, from formulation to commercial production. These factors collectively contribute to the prominence of the pharmaceuticals segment in the global CMO/CDMO market.

Asia Pacific is expected to emerge as the second-leading region in the CMO/CDMO Market, following North America. The region boasts a rapidly expanding pharmaceutical and biotechnology industry, driven by increasing healthcare expenditure, a growing population, and rising demand for innovative therapies. Secondly, Asia Pacific offers a competitive advantage in terms of cost-effective manufacturing capabilities, skilled workforce, and robust regulatory frameworks conducive to outsourcing partnerships. Additionally, strategic investments in infrastructure and technology advancements have further strengthened the region’s position as a preferred destination for CMO/CDMO services.

Moreover, favourable government policies, such as tax incentives and streamlined approval processes, attract multinational pharmaceutical companies to establish partnerships and manufacturing facilities in the region, contributing to its emergence as a key player in the global CMO/CDMO market.

Competitive Landscape

Major players such as Lonza Group, Thermo Fisher Scientific, and Catalent, Inc. dominate the market with extensive service offerings and global presence. Additionally, there is a growing presence of regional players and niche service providers catering to specific therapeutic areas or manufacturing technologies, fostering competition and innovation within the industry.

Some of the players operating in the CMO/CDMO Market are

  • AXXELENT
  • BDR Pharmaceuticals Internationals Pvt. Ltd.
  • Catalent
  • CoreRx
  • Eurofins Scientific
  • HIKAL Ltd.
  • Idifarma
  • KBI Biopharma.
  • Laurus Synthesis
  • Lonza
  • mAbxience
  • Piramal Pharma Solutions
  • QuayPharma
  • Sai Life Sciences
  • Thermo Fisher Scientific
  • Other Industry Participants

Global CMO/CDMO Market: Key Insights

Report Specifications Details
Market Revenue in 2023 US$ 21.2 Bn
Market Size Forecast by 2034 US$ 42.4 Bn
Growth Rate (CAGR) 6.5%
Historic Data 2016 – 2022
Base Year for Estimation 2023
Forecast Period 2024 – 2034
Report Inclusions Market Size & Estimates, Market Dynamics, Competitive Scenario, Trends, Growth Factors, Market Determinants, Key Investment Segmentation, Product/Service/Solutions Benchmarking
Segments Covered By Product Type, By Therapeutic Area, By End Use Industry
Regions Covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Countries Covered U.S., Canada, Mexico, Rest of North America,  France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe,  China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific,  Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa,  Brazil, Argentina, Rest of Latin America
Key Players AXXELENT, BDR Pharmaceuticals Internationals Pvt. Ltd., Catalent, CoreRx, Eurofins Scientific, HIKAL Ltd., Idifarma, KBI Biopharma., Laurus Synthesis, Lonza, mAbxience, Piramal Pharma Solutions, QuayPharma, Sai Life Sciences, Thermo Fisher Scientific, Other Market Participants
Customization Scope Customization allows for the inclusion/modification of content pertaining to geographical regions, countries, and specific market segments.
Pricing & Procurement Options Explore purchase options tailored to your specific research requirements
Contact Details Consult With Our Expert

Japan (Toll-Free):  +81 663-386-8111

South Korea (Toll-Free):  +82-808- 703-126

Saudi Arabia (Toll-Free):  +966 800-850-1643

United Kingdom: +44 753-710-5080

United States: +1 302-232-5106

E-mail:  askanexpert@thenicheresearch.com

 

Global CMO/CDMO Market

By Service Type

  • Development Services
    • Formulation Development
    • Process Development
    • Analytical Development
    • Preclinical and Clinical Manufacturing
  • Manufacturing Services
    • API Manufacturing
    • Drug Product Manufacturing
    • Biologics Manufacturing
    • Medical Device Manufacturing
    • Packaging and Labelling
    • Supply Chain Management
  • Regulatory and Compliance Services
    • Regulatory Consulting
    • Quality Assurance and Control
    • Validation Services
  • Technology Transfer Services
  • Others

By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiovascular
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

By End Use Industry

  • Pharmaceuticals
  • Biotechnology
  • Medical Devices
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

Report Coverage 

Table of Contents

.

1.Market Scope
1.1.Market Segmentation

1.2.Years Considered
1.2.1.Historic Years: 2016 – 2022

1.2.2.Base Year: 2023

1.2.3.Forecast Years: 2024 – 2034

2.Key Target Audiences

3.Research Methodology
3.1.Primary Research
3.1.1.Research Questionnaire

3.1.2.Global Percentage Breakdown

3.1.3.Primary Interviews: Key Opinion Leaders (KOLs)

3.2.Secondary Research
3.2.1.Paid Databases

3.2.2.Secondary Sources

3.3.Market Size Estimates
3.3.1.Top-Down Approach

3.3.2.Bottom-Up Approach

3.4.Data Triangulation Methodology

3.5.Research Assumptions

4.Recommendations and Insights from AMI’s Perspective**

5.Holistic Overview of CMO/CDMO Market

6.Market Synopsis: CMO/CDMO Market

7.CMO/CDMO Market Analysis: Qualitative Perspective
7.1.Introduction
7.1.1.Product Definition

7.1.2.Industry Development

7.2.Market Dynamics
7.2.1.Drivers

7.2.2.Restraints

7.2.3.Opportunities

7.2.4.Challenges

7.3.Trends in CMO/CDMO Market

7.4.Market Determinants Radar Chart

7.5.Macro-Economic and Micro-Economic Indicators: CMO/CDMO Market

7.6.Industry Gross Margin Overview

7.7.Porter’s Five Force Analysis

7.8.Impact of Covid-19 on CMO/CDMO Market

7.9.PESTEL Analysis

7.10.Value Chain Analysis

7.11.Pricing Analysis, By Region (2023)
7.11.1.North America

7.11.2.Europe

7.11.3.Asia Pacific

7.11.4.Middle East and Africa

7.11.5.Latin America

8.Global CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
8.1.Overview
8.1.1.Global CMO/CDMO Market Revenue (US$ Mn)

8.2.Global CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
8.2.1.Development Services (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Formulation Development, Process Development, Analytical Development, Preclinical and Clinical Manufacturing)
8.2.1.1.Formulation Development

8.2.1.2.Process Development

8.2.1.3.Analytical Development

8.2.1.4.Preclinical and Clinical Manufacturing

8.2.2.Manufacturing Services (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on API Manufacturing, Drug Product Manufacturing, Biologics Manufacturing, Medical Device Manufacturing, Packaging and Labeling, Supply Chain Management)
8.2.2.1.API Manufacturing

8.2.2.2.Drug Product Manufacturing

8.2.2.3.Biologics Manufacturing

8.2.2.4.Medical Device Manufacturing

8.2.2.5.Packaging and Labeling

8.2.2.6.Supply Chain Management

8.2.3.Regulatory and Compliance Services (Definition, Market Estimation and Penetration, 2016 – 2023, Market Estimation (2016 – 2023), Market Forecast (2024 – 2034), Compound Annual Growth Rate (CAGR), Regional Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin America) and Information on Regulatory Consulting, Quality Assurance and Control, Validation Services)
8.2.3.1.Regulatory Consulting

8.2.3.2.Quality Assurance and Control

8.2.3.3.Validation Services

8.2.4.Technology Transfer Services
8.2.4.1.Definition

8.2.4.2.Market Estimation and Penetration, 2016 – 2023

8.2.4.3.Market Forecast, 2024 – 2034

8.2.4.4.Compound Annual Growth Rate (CAGR)

8.2.4.5.Regional Bifurcation
8.2.4.5.1.North America
8.2.4.5.1.1.Market Estimation, 2016 – 2023

8.2.4.5.1.2.Market Forecast, 2024 – 2034

8.2.4.5.2.Europe
8.2.4.5.2.1.Market Estimation, 2016 – 2023

8.2.4.5.2.2.Market Forecast, 2024 – 2034

8.2.4.5.3.Asia Pacific
8.2.4.5.3.1.Market Estimation, 2016 – 2023

8.2.4.5.3.2.Market Forecast, 2024 – 2034

8.2.4.5.4.Middle East and Africa
8.2.4.5.4.1.Market Estimation, 2016 – 2023

8.2.4.5.4.2.Market Forecast, 2024 – 2034

8.2.4.5.5.Latin America
8.2.4.5.5.1.Market Estimation, 2016 – 2023

8.2.4.5.5.2.Market Forecast, 2024 – 2034

8.2.5.Others
8.2.5.1.Definition

8.2.5.2.Market Estimation and Penetration, 2016 – 2023

8.2.5.3.Market Forecast, 2024 – 2034

8.2.5.4.Compound Annual Growth Rate (CAGR)

8.2.5.5.Regional Bifurcation
8.2.5.5.1.North America
8.2.5.5.1.1.Market Estimation, 2016 – 2023

8.2.5.5.1.2.Market Forecast, 2024 – 2034

8.2.5.5.2.Europe
8.2.5.5.2.1.Market Estimation, 2016 – 2023

8.2.5.5.2.2.Market Forecast, 2024 – 2034

8.2.5.5.3.Asia Pacific
8.2.5.5.3.1.Market Estimation, 2016 – 2023

8.2.5.5.3.2.Market Forecast, 2024 – 2034

8.2.5.5.4.Middle East and Africa
8.2.5.5.4.1.Market Estimation, 2016 – 2023

8.2.5.5.4.2.Market Forecast, 2024 – 2034

8.2.5.5.5.Latin America
8.2.5.5.5.1.Market Estimation, 2016 – 2023

8.2.5.5.5.2.Market Forecast, 2024 – 2034

8.3.Key Segment for Channeling Investments
8.3.1.By Service Type

9.Global CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
9.1.Overview

9.2.Global CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
9.2.1.Oncology
9.2.1.1.Definition

9.2.1.2.Market Estimation and Penetration, 2016 – 2023

9.2.1.3.Market Forecast, 2024 – 2034

9.2.1.4.Compound Annual Growth Rate (CAGR)

9.2.1.5.Regional Bifurcation
9.2.1.5.1.North America
9.2.1.5.1.1.Market Estimation, 2016 – 2023

9.2.1.5.1.2.Market Forecast, 2024 – 2034

9.2.1.5.2.Europe
9.2.1.5.2.1.Market Estimation, 2016 – 2023

9.2.1.5.2.2.Market Forecast, 2024 – 2034

9.2.1.5.3.Asia Pacific
9.2.1.5.3.1.Market Estimation, 2016 – 2023

9.2.1.5.3.2.Market Forecast, 2024 – 2034

9.2.1.5.4.Middle East and Africa
9.2.1.5.4.1.Market Estimation, 2016 – 2023

9.2.1.5.4.2.Market Forecast, 2024 – 2034

9.2.1.5.5.Latin America
9.2.1.5.5.1.Market Estimation, 2016 – 2023

9.2.1.5.5.2.Market Forecast, 2024 – 2034

9.2.2.Neurology
9.2.2.1.Definition

9.2.2.2.Market Estimation and Penetration, 2016 – 2023

9.2.2.3.Market Forecast, 2024 – 2034

9.2.2.4.Compound Annual Growth Rate (CAGR)

9.2.2.5.Regional Bifurcation
9.2.2.5.1.North America
9.2.2.5.1.1.Market Estimation, 2016 – 2023

9.2.2.5.1.2.Market Forecast, 2024 – 2034

9.2.2.5.2.Europe
9.2.2.5.2.1.Market Estimation, 2016 – 2023

9.2.2.5.2.2.Market Forecast, 2024 – 2034

9.2.2.5.3.Asia Pacific
9.2.2.5.3.1.Market Estimation, 2016 – 2023

9.2.2.5.3.2.Market Forecast, 2024 – 2034

9.2.2.5.4.Middle East and Africa
9.2.2.5.4.1.Market Estimation, 2016 – 2023

9.2.2.5.4.2.Market Forecast, 2024 – 2034

9.2.2.5.5.Latin America
9.2.2.5.5.1.Market Estimation, 2016 – 2023

9.2.2.5.5.2.Market Forecast, 2024 – 2034

9.2.3.Cardiovascular
9.2.3.1.Definition

9.2.3.2.Market Estimation and Penetration, 2016 – 2023

9.2.3.3.Market Forecast, 2024 – 2034

9.2.3.4.Compound Annual Growth Rate (CAGR)

9.2.3.5.Regional Bifurcation
9.2.3.5.1.North America
9.2.3.5.1.1.Market Estimation, 2016 – 2023

9.2.3.5.1.2.Market Forecast, 2024 – 2034

9.2.3.5.2.Europe
9.2.3.5.2.1.Market Estimation, 2016 – 2023

9.2.3.5.2.2.Market Forecast, 2024 – 2034

9.2.3.5.3.Asia Pacific
9.2.3.5.3.1.Market Estimation, 2016 – 2023

9.2.3.5.3.2.Market Forecast, 2024 – 2034

9.2.3.5.4.Middle East and Africa
9.2.3.5.4.1.Market Estimation, 2016 – 2023

9.2.3.5.4.2.Market Forecast, 2024 – 2034

9.2.3.5.5.Latin America
9.2.3.5.5.1.Market Estimation, 2016 – 2023

9.2.3.5.5.2.Market Forecast, 2024 – 2034

9.2.4.Infectious Diseases
9.2.4.1.Definition

9.2.4.2.Market Estimation and Penetration, 2016 – 2023

9.2.4.3.Market Forecast, 2024 – 2034

9.2.4.4.Compound Annual Growth Rate (CAGR)

9.2.4.5.Regional Bifurcation
9.2.4.5.1.North America
9.2.4.5.1.1.Market Estimation, 2016 – 2023

9.2.4.5.1.2.Market Forecast, 2024 – 2034

9.2.4.5.2.Europe
9.2.4.5.2.1.Market Estimation, 2016 – 2023

9.2.4.5.2.2.Market Forecast, 2024 – 2034

9.2.4.5.3.Asia Pacific
9.2.4.5.3.1.Market Estimation, 2016 – 2023

9.2.4.5.3.2.Market Forecast, 2024 – 2034

9.2.4.5.4.Middle East and Africa
9.2.4.5.4.1.Market Estimation, 2016 – 2023

9.2.4.5.4.2.Market Forecast, 2024 – 2034

9.2.4.5.5.Latin America
9.2.4.5.5.1.Market Estimation, 2016 – 2023

9.2.4.5.5.2.Market Forecast, 2024 – 2034

9.2.5.Autoimmune Disorders
9.2.5.1.Definition

9.2.5.2.Market Estimation and Penetration, 2016 – 2023

9.2.5.3.Market Forecast, 2024 – 2034

9.2.5.4.Compound Annual Growth Rate (CAGR)

9.2.5.5.Regional Bifurcation
9.2.5.5.1.North America
9.2.5.5.1.1.Market Estimation, 2016 – 2023

9.2.5.5.1.2.Market Forecast, 2024 – 2034

9.2.5.5.2.Europe
9.2.5.5.2.1.Market Estimation, 2016 – 2023

9.2.5.5.2.2.Market Forecast, 2024 – 2034

9.2.5.5.3.Asia Pacific
9.2.5.5.3.1.Market Estimation, 2016 – 2023

9.2.5.5.3.2.Market Forecast, 2024 – 2034

9.2.5.5.4.Middle East and Africa
9.2.5.5.4.1.Market Estimation, 2016 – 2023

9.2.5.5.4.2.Market Forecast, 2024 – 2034

9.2.5.5.5.Latin America
9.2.5.5.5.1.Market Estimation, 2016 – 2023

9.2.5.5.5.2.Market Forecast, 2024 – 2034

9.2.6.Others
9.2.6.1.Definition

9.2.6.2.Market Estimation and Penetration, 2016 – 2023

9.2.6.3.Market Forecast, 2024 – 2034

9.2.6.4.Compound Annual Growth Rate (CAGR)

9.2.6.5.Regional Bifurcation
9.2.6.5.1.North America
9.2.6.5.1.1.Market Estimation, 2016 – 2023

9.2.6.5.1.2.Market Forecast, 2024 – 2034

9.2.6.5.2.Europe
9.2.6.5.2.1.Market Estimation, 2016 – 2023

9.2.6.5.2.2.Market Forecast, 2024 – 2034

9.2.6.5.3.Asia Pacific
9.2.6.5.3.1.Market Estimation, 2016 – 2023

9.2.6.5.3.2.Market Forecast, 2024 – 2034

9.2.6.5.4.Middle East and Africa
9.2.6.5.4.1.Market Estimation, 2016 – 2023

9.2.6.5.4.2.Market Forecast, 2024 – 2034

9.2.6.5.5.Latin America
9.2.6.5.5.1.Market Estimation, 2016 – 2023

9.2.6.5.5.2.Market Forecast, 2024 – 2034

9.3.Key Segment for Channeling Investments
9.3.1.By Therapeutic Area

10.Global CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
10.1.Overview

10.2.Global CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
10.2.1.Pharmaceuticals
10.2.1.1.Definition

10.2.1.2.Market Estimation and Penetration, 2016 – 2023

10.2.1.3.Market Forecast, 2024 – 2034

10.2.1.4.Compound Annual Growth Rate (CAGR)

10.2.1.5.Regional Bifurcation
10.2.1.5.1.North America
10.2.1.5.1.1.Market Estimation, 2016 – 2023

10.2.1.5.1.2.Market Forecast, 2024 – 2034

10.2.1.5.2.Europe
10.2.1.5.2.1.Market Estimation, 2016 – 2023

10.2.1.5.2.2.Market Forecast, 2024 – 2034

10.2.1.5.3.Asia Pacific
10.2.1.5.3.1.Market Estimation, 2016 – 2023

10.2.1.5.3.2.Market Forecast, 2024 – 2034

10.2.1.5.4.Middle East and Africa
10.2.1.5.4.1.Market Estimation, 2016 – 2023

10.2.1.5.4.2.Market Forecast, 2024 – 2034

10.2.1.5.5.Latin America
10.2.1.5.5.1.Market Estimation, 2016 – 2023

10.2.1.5.5.2.Market Forecast, 2024 – 2034

10.2.2.Biotechnology
10.2.2.1.Definition

10.2.2.2.Market Estimation and Penetration, 2016 – 2023

10.2.2.3.Market Forecast, 2024 – 2034

10.2.2.4.Compound Annual Growth Rate (CAGR)

10.2.2.5.Regional Bifurcation
10.2.2.5.1.North America
10.2.2.5.1.1.Market Estimation, 2016 – 2023

10.2.2.5.1.2.Market Forecast, 2024 – 2034

10.2.2.5.2.Europe
10.2.2.5.2.1.Market Estimation, 2016 – 2023

10.2.2.5.2.2.Market Forecast, 2024 – 2034

10.2.2.5.3.Asia Pacific
10.2.2.5.3.1.Market Estimation, 2016 – 2023

10.2.2.5.3.2.Market Forecast, 2024 – 2034

10.2.2.5.4.Middle East and Africa
10.2.2.5.4.1.Market Estimation, 2016 – 2023

10.2.2.5.4.2.Market Forecast, 2024 – 2034

10.2.2.5.5.Latin America
10.2.2.5.5.1.Market Estimation, 2016 – 2023

10.2.2.5.5.2.Market Forecast, 2024 – 2034

10.2.3.Medical Devices
10.2.3.1.Definition

10.2.3.2.Market Estimation and Penetration, 2016 – 2023

10.2.3.3.Market Forecast, 2024 – 2034

10.2.3.4.Compound Annual Growth Rate (CAGR)

10.2.3.5.Regional Bifurcation
10.2.3.5.1.North America
10.2.3.5.1.1.Market Estimation, 2016 – 2023

10.2.3.5.1.2.Market Forecast, 2024 – 2034

10.2.3.5.2.Europe
10.2.3.5.2.1.Market Estimation, 2016 – 2023

10.2.3.5.2.2.Market Forecast, 2024 – 2034

10.2.3.5.3.Asia Pacific
10.2.3.5.3.1.Market Estimation, 2016 – 2023

10.2.3.5.3.2.Market Forecast, 2024 – 2034

10.2.3.5.4.Middle East and Africa
10.2.3.5.4.1.Market Estimation, 2016 – 2023

10.2.3.5.4.2.Market Forecast, 2024 – 2034

10.2.3.5.5.Latin America
10.2.3.5.5.1.Market Estimation, 2016 – 2023

10.2.3.5.5.2.Market Forecast, 2024 – 2034

10.2.4.Others
10.2.4.1.Definition

10.2.4.2.Market Estimation and Penetration, 2016 – 2023

10.2.4.3.Market Forecast, 2024 – 2034

10.2.4.4.Compound Annual Growth Rate (CAGR)

10.2.4.5.Regional Bifurcation
10.2.4.5.1.North America
10.2.4.5.1.1.Market Estimation, 2016 – 2023

10.2.4.5.1.2.Market Forecast, 2024 – 2034

10.2.4.5.2.Europe
10.2.4.5.2.1.Market Estimation, 2016 – 2023

10.2.4.5.2.2.Market Forecast, 2024 – 2034

10.2.4.5.3.Asia Pacific
10.2.4.5.3.1.Market Estimation, 2016 – 2023

10.2.4.5.3.2.Market Forecast, 2024 – 2034

10.2.4.5.4.Middle East and Africa
10.2.4.5.4.1.Market Estimation, 2016 – 2023

10.2.4.5.4.2.Market Forecast, 2024 – 2034

10.2.4.5.5.Latin America
10.2.4.5.5.1.Market Estimation, 2016 – 2023

10.2.4.5.5.2.Market Forecast, 2024 – 2034

10.3.Key Segment for Channeling Investments
10.3.1.By End Use Industry

11.North America CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
11.1.Overview
11.1.1.North America CMO/CDMO Market Revenue (US$ Mn)

11.2.North America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
11.2.1.Development Services
11.2.1.1.Formulation Development

11.2.1.2.Process Development

11.2.1.3.Analytical Development

11.2.1.4.Preclinical and Clinical Manufacturing

11.2.2.Manufacturing Services
11.2.2.1.API Manufacturing

11.2.2.2.Drug Product Manufacturing

11.2.2.3.Biologics Manufacturing

11.2.2.4.Medical Device Manufacturing

11.2.2.5.Packaging and Labeling

11.2.2.6.Supply Chain Management

11.2.3.Regulatory and Compliance Services
11.2.3.1.Regulatory Consulting

11.2.3.2.Quality Assurance and Control

11.2.3.3.Validation Services

11.2.4.Technology Transfer Services

11.2.5.Others

11.3.North America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.3.1.Oncology

11.3.2.Neurology

11.3.3.Cardiovascular

11.3.4.Infectious Diseases

11.3.5.Autoimmune Disorders

11.3.6.Others

11.4.North America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
11.4.1.Pharmaceuticals

11.4.2.Biotechnology

11.4.3.Medical Devices

11.4.4.Others

11.5.North America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1.U.S
11.5.1.1.U.S CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
11.5.1.1.1.Development Services
11.5.1.1.1.1.Formulation Development

11.5.1.1.1.2.Process Development

11.5.1.1.1.3.Analytical Development

11.5.1.1.1.4.Preclinical and Clinical Manufacturing

11.5.1.1.2.Manufacturing Services
11.5.1.1.2.1.API Manufacturing

11.5.1.1.2.2.Drug Product Manufacturing

11.5.1.1.2.3.Biologics Manufacturing

11.5.1.1.2.4.Medical Device Manufacturing

11.5.1.1.2.5.Packaging and Labeling

11.5.1.1.2.6.Supply Chain Management

11.5.1.1.3.Regulatory and Compliance Services
11.5.1.1.3.1.Regulatory Consulting

11.5.1.1.3.2.Quality Assurance and Control

11.5.1.1.3.3.Validation Services

11.5.1.1.4.Technology Transfer Services

11.5.1.1.5.Others

11.5.1.2.U.S CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.1.2.1.Oncology

11.5.1.2.2.Neurology

11.5.1.2.3.Cardiovascular

11.5.1.2.4.Infectious Diseases

11.5.1.2.5.Autoimmune Disorders

11.5.1.2.6.Others

11.5.1.3.U.S CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
11.5.1.3.1.Pharmaceuticals

11.5.1.3.2.Biotechnology

11.5.1.3.3.Medical Devices

11.5.1.3.4.Others

11.5.2.Canada
11.5.2.1.Canada CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
11.5.2.1.1.Development Services
11.5.2.1.1.1.Formulation Development

11.5.2.1.1.2.Process Development

11.5.2.1.1.3.Analytical Development

11.5.2.1.1.4.Preclinical and Clinical Manufacturing

11.5.2.1.2.Manufacturing Services
11.5.2.1.2.1.API Manufacturing

11.5.2.1.2.2.Drug Product Manufacturing

11.5.2.1.2.3.Biologics Manufacturing

11.5.2.1.2.4.Medical Device Manufacturing

11.5.2.1.2.5.Packaging and Labeling

11.5.2.1.2.6.Supply Chain Management

11.5.2.1.3.Regulatory and Compliance Services
11.5.2.1.3.1.Regulatory Consulting

11.5.2.1.3.2.Quality Assurance and Control

11.5.2.1.3.3.Validation Services

11.5.2.1.4.Technology Transfer Services

11.5.2.1.5.Others

11.5.2.2.Canada CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.2.2.1.Oncology

11.5.2.2.2.Neurology

11.5.2.2.3.Cardiovascular

11.5.2.2.4.Infectious Diseases

11.5.2.2.5.Autoimmune Disorders

11.5.2.2.6.Others

11.5.2.3.Canada CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
11.5.2.3.1.Pharmaceuticals

11.5.2.3.2.Biotechnology

11.5.2.3.3.Medical Devices

11.5.2.3.4.Others

11.5.3.Mexico
11.5.3.1.Mexico CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
11.5.3.1.1.Development Services
11.5.3.1.1.1.Formulation Development

11.5.3.1.1.2.Process Development

11.5.3.1.1.3.Analytical Development

11.5.3.1.1.4.Preclinical and Clinical Manufacturing

11.5.3.1.2.Manufacturing Services
11.5.3.1.2.1.API Manufacturing

11.5.3.1.2.2.Drug Product Manufacturing

11.5.3.1.2.3.Biologics Manufacturing

11.5.3.1.2.4.Medical Device Manufacturing

11.5.3.1.2.5.Packaging and Labeling

11.5.3.1.2.6.Supply Chain Management

11.5.3.1.3.Regulatory and Compliance Services
11.5.3.1.3.1.Regulatory Consulting

11.5.3.1.3.2.Quality Assurance and Control

11.5.3.1.3.3.Validation Services

11.5.3.1.4.Technology Transfer Services

11.5.3.1.5.Others

11.5.3.2.Mexico CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.3.2.1.Oncology

11.5.3.2.2.Neurology

11.5.3.2.3.Cardiovascular

11.5.3.2.4.Infectious Diseases

11.5.3.2.5.Autoimmune Disorders

11.5.3.2.6.Others

11.5.3.3.Mexico CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
11.5.3.3.1.Pharmaceuticals

11.5.3.3.2.Biotechnology

11.5.3.3.3.Medical Devices

11.5.3.3.4.Others

11.5.4.Rest of North America
11.5.4.1.Rest of North America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
11.5.4.1.1.Development Services
11.5.4.1.1.1.Formulation Development

11.5.4.1.1.2.Process Development

11.5.4.1.1.3.Analytical Development

11.5.4.1.1.4.Preclinical and Clinical Manufacturing

11.5.4.1.2.Manufacturing Services
11.5.4.1.2.1.API Manufacturing

11.5.4.1.2.2.Drug Product Manufacturing

11.5.4.1.2.3.Biologics Manufacturing

11.5.4.1.2.4.Medical Device Manufacturing

11.5.4.1.2.5.Packaging and Labeling

11.5.4.1.2.6.Supply Chain Management

11.5.4.1.3.Regulatory and Compliance Services
11.5.4.1.3.1.Regulatory Consulting

11.5.4.1.3.2.Quality Assurance and Control

11.5.4.1.3.3.Validation Services

11.5.4.1.4.Technology Transfer Services

11.5.4.1.5.Others

11.5.4.2.Rest of North America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
11.5.4.2.1.Oncology

11.5.4.2.2.Neurology

11.5.4.2.3.Cardiovascular

11.5.4.2.4.Infectious Diseases

11.5.4.2.5.Autoimmune Disorders

11.5.4.2.6.Others

11.5.4.3.Rest of North America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
11.5.4.3.1.Pharmaceuticals

11.5.4.3.2.Biotechnology

11.5.4.3.3.Medical Devices

11.5.4.3.4.Others

11.6.Key Segment for Channeling Investments
11.6.1.By Country

11.6.2.By Service Type

11.6.3.By Therapeutic Area

11.6.4.By End Use Industry

12.Europe CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
12.1.Overview
12.1.1.Europe CMO/CDMO Market Revenue (US$ Mn)

12.2.Europe CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.2.1.Development Services
12.2.1.1.Formulation Development

12.2.1.2.Process Development

12.2.1.3.Analytical Development

12.2.1.4.Preclinical and Clinical Manufacturing

12.2.2.Manufacturing Services
12.2.2.1.API Manufacturing

12.2.2.2.Drug Product Manufacturing

12.2.2.3.Biologics Manufacturing

12.2.2.4.Medical Device Manufacturing

12.2.2.5.Packaging and Labeling

12.2.2.6.Supply Chain Management

12.2.3.Regulatory and Compliance Services
12.2.3.1.Regulatory Consulting

12.2.3.2.Quality Assurance and Control

12.2.3.3.Validation Services

12.2.4.Technology Transfer Services

12.2.5.Others

12.3.Europe CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.3.1.Oncology

12.3.2.Neurology

12.3.3.Cardiovascular

12.3.4.Infectious Diseases

12.3.5.Autoimmune Disorders

12.3.6.Others

12.4.Europe CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.4.1.Pharmaceuticals

12.4.2.Biotechnology

12.4.3.Medical Devices

12.4.4.Others

12.5.Europe CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
12.5.1.France
12.5.1.1.France CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.1.1.1.Development Services
12.5.1.1.1.1.Formulation Development

12.5.1.1.1.2.Process Development

12.5.1.1.1.3.Analytical Development

12.5.1.1.1.4.Preclinical and Clinical Manufacturing

12.5.1.1.2.Manufacturing Services
12.5.1.1.2.1.API Manufacturing

12.5.1.1.2.2.Drug Product Manufacturing

12.5.1.1.2.3.Biologics Manufacturing

12.5.1.1.2.4.Medical Device Manufacturing

12.5.1.1.2.5.Packaging and Labeling

12.5.1.1.2.6.Supply Chain Management

12.5.1.1.3.Regulatory and Compliance Services
12.5.1.1.3.1.Regulatory Consulting

12.5.1.1.3.2.Quality Assurance and Control

12.5.1.1.3.3.Validation Services

12.5.1.1.4.Technology Transfer Services

12.5.1.1.5.Others

12.5.1.2.France CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.1.2.1.Oncology

12.5.1.2.2.Neurology

12.5.1.2.3.Cardiovascular

12.5.1.2.4.Infectious Diseases

12.5.1.2.5.Autoimmune Disorders

12.5.1.2.6.Others

12.5.1.3.France CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.1.3.1.Pharmaceuticals

12.5.1.3.2.Biotechnology

12.5.1.3.3.Medical Devices

12.5.1.3.4.Others

12.5.2.The UK
12.5.2.1.The UK CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.2.1.1.Development Services
12.5.2.1.1.1.Formulation Development

12.5.2.1.1.2.Process Development

12.5.2.1.1.3.Analytical Development

12.5.2.1.1.4.Preclinical and Clinical Manufacturing

12.5.2.1.2.Manufacturing Services
12.5.2.1.2.1.API Manufacturing

12.5.2.1.2.2.Drug Product Manufacturing

12.5.2.1.2.3.Biologics Manufacturing

12.5.2.1.2.4.Medical Device Manufacturing

12.5.2.1.2.5.Packaging and Labeling

12.5.2.1.2.6.Supply Chain Management

12.5.2.1.3.Regulatory and Compliance Services
12.5.2.1.3.1.Regulatory Consulting

12.5.2.1.3.2.Quality Assurance and Control

12.5.2.1.3.3.Validation Services

12.5.2.1.4.Technology Transfer Services

12.5.2.1.5.Others

12.5.2.2.The UK CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.2.2.1.Oncology

12.5.2.2.2.Neurology

12.5.2.2.3.Cardiovascular

12.5.2.2.4.Infectious Diseases

12.5.2.2.5.Autoimmune Disorders

12.5.2.2.6.Others

12.5.2.3.The UK CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.2.3.1.Pharmaceuticals

12.5.2.3.2.Biotechnology

12.5.2.3.3.Medical Devices

12.5.2.3.4.Others

12.5.3.Spain
12.5.3.1.Spain CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.3.1.1.Development Services
12.5.3.1.1.1.Formulation Development

12.5.3.1.1.2.Process Development

12.5.3.1.1.3.Analytical Development

12.5.3.1.1.4.Preclinical and Clinical Manufacturing

12.5.3.1.2.Manufacturing Services
12.5.3.1.2.1.API Manufacturing

12.5.3.1.2.2.Drug Product Manufacturing

12.5.3.1.2.3.Biologics Manufacturing

12.5.3.1.2.4.Medical Device Manufacturing

12.5.3.1.2.5.Packaging and Labeling

12.5.3.1.2.6.Supply Chain Management

12.5.3.1.3.Regulatory and Compliance Services
12.5.3.1.3.1.Regulatory Consulting

12.5.3.1.3.2.Quality Assurance and Control

12.5.3.1.3.3.Validation Services

12.5.3.1.4.Technology Transfer Services

12.5.3.1.5.Others

12.5.3.2.Spain CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.3.2.1.Oncology

12.5.3.2.2.Neurology

12.5.3.2.3.Cardiovascular

12.5.3.2.4.Infectious Diseases

12.5.3.2.5.Autoimmune Disorders

12.5.3.2.6.Others

12.5.3.3.Spain CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.3.3.1.Pharmaceuticals

12.5.3.3.2.Biotechnology

12.5.3.3.3.Medical Devices

12.5.3.3.4.Others

12.5.4.Germany
12.5.4.1.Germany CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.4.1.1.Development Services
12.5.4.1.1.1.Formulation Development

12.5.4.1.1.2.Process Development

12.5.4.1.1.3.Analytical Development

12.5.4.1.1.4.Preclinical and Clinical Manufacturing

12.5.4.1.2.Manufacturing Services
12.5.4.1.2.1.API Manufacturing

12.5.4.1.2.2.Drug Product Manufacturing

12.5.4.1.2.3.Biologics Manufacturing

12.5.4.1.2.4.Medical Device Manufacturing

12.5.4.1.2.5.Packaging and Labeling

12.5.4.1.2.6.Supply Chain Management

12.5.4.1.3.Regulatory and Compliance Services
12.5.4.1.3.1.Regulatory Consulting

12.5.4.1.3.2.Quality Assurance and Control

12.5.4.1.3.3.Validation Services

12.5.4.1.4.Technology Transfer Services

12.5.4.1.5.Others

12.5.4.2.Germany CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.4.2.1.Oncology

12.5.4.2.2.Neurology

12.5.4.2.3.Cardiovascular

12.5.4.2.4.Infectious Diseases

12.5.4.2.5.Autoimmune Disorders

12.5.4.2.6.Others

12.5.4.3.Germany CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.4.3.1.Pharmaceuticals

12.5.4.3.2.Biotechnology

12.5.4.3.3.Medical Devices

12.5.4.3.4.Others

12.5.5.Italy
12.5.5.1.Italy CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.5.1.1.Development Services
12.5.5.1.1.1.Formulation Development

12.5.5.1.1.2.Process Development

12.5.5.1.1.3.Analytical Development

12.5.5.1.1.4.Preclinical and Clinical Manufacturing

12.5.5.1.2.Manufacturing Services
12.5.5.1.2.1.API Manufacturing

12.5.5.1.2.2.Drug Product Manufacturing

12.5.5.1.2.3.Biologics Manufacturing

12.5.5.1.2.4.Medical Device Manufacturing

12.5.5.1.2.5.Packaging and Labeling

12.5.5.1.2.6.Supply Chain Management

12.5.5.1.3.Regulatory and Compliance Services
12.5.5.1.3.1.Regulatory Consulting

12.5.5.1.3.2.Quality Assurance and Control

12.5.5.1.3.3.Validation Services

12.5.5.1.4.Technology Transfer Services

12.5.5.1.5.Others

12.5.5.2.Italy CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.5.2.1.Oncology

12.5.5.2.2.Neurology

12.5.5.2.3.Cardiovascular

12.5.5.2.4.Infectious Diseases

12.5.5.2.5.Autoimmune Disorders

12.5.5.2.6.Others

12.5.5.3.Italy CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.5.3.1.Pharmaceuticals

12.5.5.3.2.Biotechnology

12.5.5.3.3.Medical Devices

12.5.5.3.4.Others

12.5.6.Nordic Countries
12.5.6.1.Nordic Countries CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.6.1.1.Development Services
12.5.6.1.1.1.Formulation Development

12.5.6.1.1.2.Process Development

12.5.6.1.1.3.Analytical Development

12.5.6.1.1.4.Preclinical and Clinical Manufacturing

12.5.6.1.2.Manufacturing Services
12.5.6.1.2.1.API Manufacturing

12.5.6.1.2.2.Drug Product Manufacturing

12.5.6.1.2.3.Biologics Manufacturing

12.5.6.1.2.4.Medical Device Manufacturing

12.5.6.1.2.5.Packaging and Labeling

12.5.6.1.2.6.Supply Chain Management

12.5.6.1.3.Regulatory and Compliance Services
12.5.6.1.3.1.Regulatory Consulting

12.5.6.1.3.2.Quality Assurance and Control

12.5.6.1.3.3.Validation Services

12.5.6.1.4.Technology Transfer Services

12.5.6.1.5.Others

12.5.6.2.Nordic Countries CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.6.2.1.Oncology

12.5.6.2.2.Neurology

12.5.6.2.3.Cardiovascular

12.5.6.2.4.Infectious Diseases

12.5.6.2.5.Autoimmune Disorders

12.5.6.2.6.Others

12.5.6.3.Nordic Countries CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.6.3.1.Pharmaceuticals

12.5.6.3.2.Biotechnology

12.5.6.3.3.Medical Devices

12.5.6.3.4.Others

12.5.6.4.Nordic Countries CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1.Denmark

12.5.6.4.2.Finland

12.5.6.4.3.Iceland

12.5.6.4.4.Sweden

12.5.6.4.5.Norway

12.5.7.Benelux Union
12.5.7.1.Benelux Union CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.7.1.1.Development Services
12.5.7.1.1.1.Formulation Development

12.5.7.1.1.2.Process Development

12.5.7.1.1.3.Analytical Development

12.5.7.1.1.4.Preclinical and Clinical Manufacturing

12.5.7.1.2.Manufacturing Services
12.5.7.1.2.1.API Manufacturing

12.5.7.1.2.2.Drug Product Manufacturing

12.5.7.1.2.3.Biologics Manufacturing

12.5.7.1.2.4.Medical Device Manufacturing

12.5.7.1.2.5.Packaging and Labeling

12.5.7.1.2.6.Supply Chain Management

12.5.7.1.3.Regulatory and Compliance Services
12.5.7.1.3.1.Regulatory Consulting

12.5.7.1.3.2.Quality Assurance and Control

12.5.7.1.3.3.Validation Services

12.5.7.1.4.Technology Transfer Services

12.5.7.1.5.Others

12.5.7.2.Benelux Union CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.7.2.1.Oncology

12.5.7.2.2.Neurology

12.5.7.2.3.Cardiovascular

12.5.7.2.4.Infectious Diseases

12.5.7.2.5.Autoimmune Disorders

12.5.7.2.6.Others

12.5.7.3.Benelux Union CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.7.3.1.Pharmaceuticals

12.5.7.3.2.Biotechnology

12.5.7.3.3.Medical Devices

12.5.7.3.4.Others

12.5.7.4.Benelux Union CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1.Belgium

12.5.7.4.2.The Netherlands

12.5.7.4.3.Luxembourg

12.5.8.Rest of Europe
12.5.8.1.Rest of Europe CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
12.5.8.1.1.Development Services
12.5.8.1.1.1.Formulation Development

12.5.8.1.1.2.Process Development

12.5.8.1.1.3.Analytical Development

12.5.8.1.1.4.Preclinical and Clinical Manufacturing

12.5.8.1.2.Manufacturing Services
12.5.8.1.2.1.API Manufacturing

12.5.8.1.2.2.Drug Product Manufacturing

12.5.8.1.2.3.Biologics Manufacturing

12.5.8.1.2.4.Medical Device Manufacturing

12.5.8.1.2.5.Packaging and Labeling

12.5.8.1.2.6.Supply Chain Management

12.5.8.1.3.Regulatory and Compliance Services
12.5.8.1.3.1.Regulatory Consulting

12.5.8.1.3.2.Quality Assurance and Control

12.5.8.1.3.3.Validation Services

12.5.8.1.4.Technology Transfer Services

12.5.8.1.5.Others

12.5.8.2.Rest of Europe CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
12.5.8.2.1.Oncology

12.5.8.2.2.Neurology

12.5.8.2.3.Cardiovascular

12.5.8.2.4.Infectious Diseases

12.5.8.2.5.Autoimmune Disorders

12.5.8.2.6.Others

12.5.8.3.Rest of Europe CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
12.5.8.3.1.Pharmaceuticals

12.5.8.3.2.Biotechnology

12.5.8.3.3.Medical Devices

12.5.8.3.4.Others

12.6.Key Segment for Channeling Investments
12.6.1.By Country

12.6.2.By Service Type

12.6.3.By Therapeutic Area

12.6.4.By End Use Industry

13.Asia Pacific CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
13.1.Overview
13.1.1.Asia Pacific CMO/CDMO Market Revenue (US$ Mn)

13.2.Asia Pacific CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.2.1.Development Services
13.2.1.1.Formulation Development

13.2.1.2.Process Development

13.2.1.3.Analytical Development

13.2.1.4.Preclinical and Clinical Manufacturing

13.2.2.Manufacturing Services
13.2.2.1.API Manufacturing

13.2.2.2.Drug Product Manufacturing

13.2.2.3.Biologics Manufacturing

13.2.2.4.Medical Device Manufacturing

13.2.2.5.Packaging and Labeling

13.2.2.6.Supply Chain Management

13.2.3.Regulatory and Compliance Services
13.2.3.1.Regulatory Consulting

13.2.3.2.Quality Assurance and Control

13.2.3.3.Validation Services

13.2.4.Technology Transfer Services

13.2.5.Others

13.3.Asia Pacific CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.3.1.Oncology

13.3.2.Neurology

13.3.3.Cardiovascular

13.3.4.Infectious Diseases

13.3.5.Autoimmune Disorders

13.3.6.Others

13.4.Asia Pacific CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.4.1.Pharmaceuticals

13.4.2.Biotechnology

13.4.3.Medical Devices

13.4.4.Others

13.5.Asia Pacific CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1.China
13.5.1.1.China CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.1.1.1.Development Services
13.5.1.1.1.1.Formulation Development

13.5.1.1.1.2.Process Development

13.5.1.1.1.3.Analytical Development

13.5.1.1.1.4.Preclinical and Clinical Manufacturing

13.5.1.1.2.Manufacturing Services
13.5.1.1.2.1.API Manufacturing

13.5.1.1.2.2.Drug Product Manufacturing

13.5.1.1.2.3.Biologics Manufacturing

13.5.1.1.2.4.Medical Device Manufacturing

13.5.1.1.2.5.Packaging and Labeling

13.5.1.1.2.6.Supply Chain Management

13.5.1.1.3.Regulatory and Compliance Services
13.5.1.1.3.1.Regulatory Consulting

13.5.1.1.3.2.Quality Assurance and Control

13.5.1.1.3.3.Validation Services

13.5.1.1.4.Technology Transfer Services

13.5.1.1.5.Others

13.5.1.2.China CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.1.2.1.Oncology

13.5.1.2.2.Neurology

13.5.1.2.3.Cardiovascular

13.5.1.2.4.Infectious Diseases

13.5.1.2.5.Autoimmune Disorders

13.5.1.2.6.Others

13.5.1.3.China CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.1.3.1.Pharmaceuticals

13.5.1.3.2.Biotechnology

13.5.1.3.3.Medical Devices

13.5.1.3.4.Others

13.5.2.Japan
13.5.2.1.Japan CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.2.1.1.Development Services
13.5.2.1.1.1.Formulation Development

13.5.2.1.1.2.Process Development

13.5.2.1.1.3.Analytical Development

13.5.2.1.1.4.Preclinical and Clinical Manufacturing

13.5.2.1.2.Manufacturing Services
13.5.2.1.2.1.API Manufacturing

13.5.2.1.2.2.Drug Product Manufacturing

13.5.2.1.2.3.Biologics Manufacturing

13.5.2.1.2.4.Medical Device Manufacturing

13.5.2.1.2.5.Packaging and Labeling

13.5.2.1.2.6.Supply Chain Management

13.5.2.1.3.Regulatory and Compliance Services
13.5.2.1.3.1.Regulatory Consulting

13.5.2.1.3.2.Quality Assurance and Control

13.5.2.1.3.3.Validation Services

13.5.2.1.4.Technology Transfer Services

13.5.2.1.5.Others

13.5.2.2.Japan CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.2.2.1.Oncology

13.5.2.2.2.Neurology

13.5.2.2.3.Cardiovascular

13.5.2.2.4.Infectious Diseases

13.5.2.2.5.Autoimmune Disorders

13.5.2.2.6.Others

13.5.2.3.Japan CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.2.3.1.Pharmaceuticals

13.5.2.3.2.Biotechnology

13.5.2.3.3.Medical Devices

13.5.2.3.4.Others

13.5.3.India
13.5.3.1.India CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.3.1.1.Development Services
13.5.3.1.1.1.Formulation Development

13.5.3.1.1.2.Process Development

13.5.3.1.1.3.Analytical Development

13.5.3.1.1.4.Preclinical and Clinical Manufacturing

13.5.3.1.2.Manufacturing Services
13.5.3.1.2.1.API Manufacturing

13.5.3.1.2.2.Drug Product Manufacturing

13.5.3.1.2.3.Biologics Manufacturing

13.5.3.1.2.4.Medical Device Manufacturing

13.5.3.1.2.5.Packaging and Labeling

13.5.3.1.2.6.Supply Chain Management

13.5.3.1.3.Regulatory and Compliance Services
13.5.3.1.3.1.Regulatory Consulting

13.5.3.1.3.2.Quality Assurance and Control

13.5.3.1.3.3.Validation Services

13.5.3.1.4.Technology Transfer Services

13.5.3.1.5.Others

13.5.3.2.India CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.3.2.1.Oncology

13.5.3.2.2.Neurology

13.5.3.2.3.Cardiovascular

13.5.3.2.4.Infectious Diseases

13.5.3.2.5.Autoimmune Disorders

13.5.3.2.6.Others

13.5.3.3.India CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.3.3.1.Pharmaceuticals

13.5.3.3.2.Biotechnology

13.5.3.3.3.Medical Devices

13.5.3.3.4.Others

13.5.4.New Zealand
13.5.4.1.New Zealand CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.4.1.1.Development Services
13.5.4.1.1.1.Formulation Development

13.5.4.1.1.2.Process Development

13.5.4.1.1.3.Analytical Development

13.5.4.1.1.4.Preclinical and Clinical Manufacturing

13.5.4.1.2.Manufacturing Services
13.5.4.1.2.1.API Manufacturing

13.5.4.1.2.2.Drug Product Manufacturing

13.5.4.1.2.3.Biologics Manufacturing

13.5.4.1.2.4.Medical Device Manufacturing

13.5.4.1.2.5.Packaging and Labeling

13.5.4.1.2.6.Supply Chain Management

13.5.4.1.3.Regulatory and Compliance Services
13.5.4.1.3.1.Regulatory Consulting

13.5.4.1.3.2.Quality Assurance and Control

13.5.4.1.3.3.Validation Services

13.5.4.1.4.Technology Transfer Services

13.5.4.1.5.Others

13.5.4.2.New Zealand CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.4.2.1.Oncology

13.5.4.2.2.Neurology

13.5.4.2.3.Cardiovascular

13.5.4.2.4.Infectious Diseases

13.5.4.2.5.Autoimmune Disorders

13.5.4.2.6.Others

13.5.4.3.New Zealand CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.4.3.1.Pharmaceuticals

13.5.4.3.2.Biotechnology

13.5.4.3.3.Medical Devices

13.5.4.3.4.Others

13.5.5.Australia
13.5.5.1.Australia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.5.1.1.Development Services
13.5.5.1.1.1.Formulation Development

13.5.5.1.1.2.Process Development

13.5.5.1.1.3.Analytical Development

13.5.5.1.1.4.Preclinical and Clinical Manufacturing

13.5.5.1.2.Manufacturing Services
13.5.5.1.2.1.API Manufacturing

13.5.5.1.2.2.Drug Product Manufacturing

13.5.5.1.2.3.Biologics Manufacturing

13.5.5.1.2.4.Medical Device Manufacturing

13.5.5.1.2.5.Packaging and Labeling

13.5.5.1.2.6.Supply Chain Management

13.5.5.1.3.Regulatory and Compliance Services
13.5.5.1.3.1.Regulatory Consulting

13.5.5.1.3.2.Quality Assurance and Control

13.5.5.1.3.3.Validation Services

13.5.5.1.4.Technology Transfer Services

13.5.5.1.5.Others

13.5.5.2.Australia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.5.2.1.Oncology

13.5.5.2.2.Neurology

13.5.5.2.3.Cardiovascular

13.5.5.2.4.Infectious Diseases

13.5.5.2.5.Autoimmune Disorders

13.5.5.2.6.Others

13.5.5.3.Australia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.5.3.1.Pharmaceuticals

13.5.5.3.2.Biotechnology

13.5.5.3.3.Medical Devices

13.5.5.3.4.Others

13.5.6.South Korea
13.5.6.1.South Korea CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.6.1.1.Development Services
13.5.6.1.1.1.Formulation Development

13.5.6.1.1.2.Process Development

13.5.6.1.1.3.Analytical Development

13.5.6.1.1.4.Preclinical and Clinical Manufacturing

13.5.6.1.2.Manufacturing Services
13.5.6.1.2.1.API Manufacturing

13.5.6.1.2.2.Drug Product Manufacturing

13.5.6.1.2.3.Biologics Manufacturing

13.5.6.1.2.4.Medical Device Manufacturing

13.5.6.1.2.5.Packaging and Labeling

13.5.6.1.2.6.Supply Chain Management

13.5.6.1.3.Regulatory and Compliance Services
13.5.6.1.3.1.Regulatory Consulting

13.5.6.1.3.2.Quality Assurance and Control

13.5.6.1.3.3.Validation Services

13.5.6.1.4.Technology Transfer Services

13.5.6.1.5.Others

13.5.6.2.South Korea CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.6.2.1.Oncology

13.5.6.2.2.Neurology

13.5.6.2.3.Cardiovascular

13.5.6.2.4.Infectious Diseases

13.5.6.2.5.Autoimmune Disorders

13.5.6.2.6.Others

13.5.6.3.South Korea CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.6.3.1.Pharmaceuticals

13.5.6.3.2.Biotechnology

13.5.6.3.3.Medical Devices

13.5.6.3.4.Others

13.5.7.Southeast Asia
13.5.7.1.Southeast Asia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.7.1.1.Development Services
13.5.7.1.1.1.Formulation Development

13.5.7.1.1.2.Process Development

13.5.7.1.1.3.Analytical Development

13.5.7.1.1.4.Preclinical and Clinical Manufacturing

13.5.7.1.2.Manufacturing Services
13.5.7.1.2.1.API Manufacturing

13.5.7.1.2.2.Drug Product Manufacturing

13.5.7.1.2.3.Biologics Manufacturing

13.5.7.1.2.4.Medical Device Manufacturing

13.5.7.1.2.5.Packaging and Labeling

13.5.7.1.2.6.Supply Chain Management

13.5.7.1.3.Regulatory and Compliance Services
13.5.7.1.3.1.Regulatory Consulting

13.5.7.1.3.2.Quality Assurance and Control

13.5.7.1.3.3.Validation Services

13.5.7.1.4.Technology Transfer Services

13.5.7.1.5.Others

13.5.7.2.Southeast Asia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.7.2.1.Oncology

13.5.7.2.2.Neurology

13.5.7.2.3.Cardiovascular

13.5.7.2.4.Infectious Diseases

13.5.7.2.5.Autoimmune Disorders

13.5.7.2.6.Others

13.5.7.3.Southeast Asia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.7.3.1.Pharmaceuticals

13.5.7.3.2.Biotechnology

13.5.7.3.3.Medical Devices

13.5.7.3.4.Others

13.5.7.4.Southeast Asia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1.Indonesia

13.5.7.4.2.Thailand

13.5.7.4.3.Malaysia

13.5.7.4.4.Singapore

13.5.7.4.5.Rest of Southeast Asia

13.5.8.Rest of Asia Pacific
13.5.8.1.Rest of Asia Pacific CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
13.5.8.1.1.Development Services
13.5.8.1.1.1.Formulation Development

13.5.8.1.1.2.Process Development

13.5.8.1.1.3.Analytical Development

13.5.8.1.1.4.Preclinical and Clinical Manufacturing

13.5.8.1.2.Manufacturing Services
13.5.8.1.2.1.API Manufacturing

13.5.8.1.2.2.Drug Product Manufacturing

13.5.8.1.2.3.Biologics Manufacturing

13.5.8.1.2.4.Medical Device Manufacturing

13.5.8.1.2.5.Packaging and Labeling

13.5.8.1.2.6.Supply Chain Management

13.5.8.1.3.Regulatory and Compliance Services
13.5.8.1.3.1.Regulatory Consulting

13.5.8.1.3.2.Quality Assurance and Control

13.5.8.1.3.3.Validation Services

13.5.8.1.4.Technology Transfer Services

13.5.8.1.5.Others

13.5.8.2.Rest of Asia Pacific CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
13.5.8.2.1.Oncology

13.5.8.2.2.Neurology

13.5.8.2.3.Cardiovascular

13.5.8.2.4.Infectious Diseases

13.5.8.2.5.Autoimmune Disorders

13.5.8.2.6.Others

13.5.8.3.Rest of Asia Pacific CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
13.5.8.3.1.Pharmaceuticals

13.5.8.3.2.Biotechnology

13.5.8.3.3.Medical Devices

13.5.8.3.4.Others

13.6.Key Segment for Channeling Investments
13.6.1.By Country

13.6.2.By Service Type

13.6.3.By Therapeutic Area

13.6.4.By End Use Industry

14.Middle East and Africa CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
14.1.Overview
14.1.1.Middle East and Africa CMO/CDMO Market Revenue (US$ Mn)

14.2.Middle East and Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
14.2.1.Development Services
14.2.1.1.Formulation Development

14.2.1.2.Process Development

14.2.1.3.Analytical Development

14.2.1.4.Preclinical and Clinical Manufacturing

14.2.2.Manufacturing Services
14.2.2.1.API Manufacturing

14.2.2.2.Drug Product Manufacturing

14.2.2.3.Biologics Manufacturing

14.2.2.4.Medical Device Manufacturing

14.2.2.5.Packaging and Labeling

14.2.2.6.Supply Chain Management

14.2.3.Regulatory and Compliance Services
14.2.3.1.Regulatory Consulting

14.2.3.2.Quality Assurance and Control

14.2.3.3.Validation Services

14.2.4.Technology Transfer Services

14.2.5.Others

14.3.Middle East and Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.3.1.Oncology

14.3.2.Neurology

14.3.3.Cardiovascular

14.3.4.Infectious Diseases

14.3.5.Autoimmune Disorders

14.3.6.Others

14.4.Middle East and Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
14.4.1.Pharmaceuticals

14.4.2.Biotechnology

14.4.3.Medical Devices

14.4.4.Others

14.5.Middle East and Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1.Saudi Arabia
14.5.1.1.Saudi Arabia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
14.5.1.1.1.Development Services
14.5.1.1.1.1.Formulation Development

14.5.1.1.1.2.Process Development

14.5.1.1.1.3.Analytical Development

14.5.1.1.1.4.Preclinical and Clinical Manufacturing

14.5.1.1.2.Manufacturing Services
14.5.1.1.2.1.API Manufacturing

14.5.1.1.2.2.Drug Product Manufacturing

14.5.1.1.2.3.Biologics Manufacturing

14.5.1.1.2.4.Medical Device Manufacturing

14.5.1.1.2.5.Packaging and Labeling

14.5.1.1.2.6.Supply Chain Management

14.5.1.1.3.Regulatory and Compliance Services
14.5.1.1.3.1.Regulatory Consulting

14.5.1.1.3.2.Quality Assurance and Control

14.5.1.1.3.3.Validation Services

14.5.1.1.4.Technology Transfer Services

14.5.1.1.5.Others

14.5.1.2.Saudi Arabia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.1.2.1.Oncology

14.5.1.2.2.Neurology

14.5.1.2.3.Cardiovascular

14.5.1.2.4.Infectious Diseases

14.5.1.2.5.Autoimmune Disorders

14.5.1.2.6.Others

14.5.1.3.Saudi Arabia CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
14.5.1.3.1.Pharmaceuticals

14.5.1.3.2.Biotechnology

14.5.1.3.3.Medical Devices

14.5.1.3.4.Others

14.5.2.UAE
14.5.2.1.UAE CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
14.5.2.1.1.Development Services
14.5.2.1.1.1.Formulation Development

14.5.2.1.1.2.Process Development

14.5.2.1.1.3.Analytical Development

14.5.2.1.1.4.Preclinical and Clinical Manufacturing

14.5.2.1.2.Manufacturing Services
14.5.2.1.2.1.API Manufacturing

14.5.2.1.2.2.Drug Product Manufacturing

14.5.2.1.2.3.Biologics Manufacturing

14.5.2.1.2.4.Medical Device Manufacturing

14.5.2.1.2.5.Packaging and Labeling

14.5.2.1.2.6.Supply Chain Management

14.5.2.1.3.Regulatory and Compliance Services
14.5.2.1.3.1.Regulatory Consulting

14.5.2.1.3.2.Quality Assurance and Control

14.5.2.1.3.3.Validation Services

14.5.2.1.4.Technology Transfer Services

14.5.2.1.5.Others

14.5.2.2.UAE CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.2.2.1.Oncology

14.5.2.2.2.Neurology

14.5.2.2.3.Cardiovascular

14.5.2.2.4.Infectious Diseases

14.5.2.2.5.Autoimmune Disorders

14.5.2.2.6.Others

14.5.2.3.UAE CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
14.5.2.3.1.Pharmaceuticals

14.5.2.3.2.Biotechnology

14.5.2.3.3.Medical Devices

14.5.2.3.4.Others

14.5.3.Egypt
14.5.3.1.Egypt CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
14.5.3.1.1.Development Services
14.5.3.1.1.1.Formulation Development

14.5.3.1.1.2.Process Development

14.5.3.1.1.3.Analytical Development

14.5.3.1.1.4.Preclinical and Clinical Manufacturing

14.5.3.1.2.Manufacturing Services
14.5.3.1.2.1.API Manufacturing

14.5.3.1.2.2.Drug Product Manufacturing

14.5.3.1.2.3.Biologics Manufacturing

14.5.3.1.2.4.Medical Device Manufacturing

14.5.3.1.2.5.Packaging and Labeling

14.5.3.1.2.6.Supply Chain Management

14.5.3.1.3.Regulatory and Compliance Services
14.5.3.1.3.1.Regulatory Consulting

14.5.3.1.3.2.Quality Assurance and Control

14.5.3.1.3.3.Validation Services

14.5.3.1.4.Technology Transfer Services

14.5.3.1.5.Others

14.5.3.2.Egypt CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.3.2.1.Oncology

14.5.3.2.2.Neurology

14.5.3.2.3.Cardiovascular

14.5.3.2.4.Infectious Diseases

14.5.3.2.5.Autoimmune Disorders

14.5.3.2.6.Others

14.5.3.3.Egypt CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
14.5.3.3.1.Pharmaceuticals

14.5.3.3.2.Biotechnology

14.5.3.3.3.Medical Devices

14.5.3.3.4.Others

14.5.4.Kuwait
14.5.4.1.Kuwait CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
14.5.4.1.1.Development Services
14.5.4.1.1.1.Formulation Development

14.5.4.1.1.2.Process Development

14.5.4.1.1.3.Analytical Development

14.5.4.1.1.4.Preclinical and Clinical Manufacturing

14.5.4.1.2.Manufacturing Services
14.5.4.1.2.1.API Manufacturing

14.5.4.1.2.2.Drug Product Manufacturing

14.5.4.1.2.3.Biologics Manufacturing

14.5.4.1.2.4.Medical Device Manufacturing

14.5.4.1.2.5.Packaging and Labeling

14.5.4.1.2.6.Supply Chain Management

14.5.4.1.3.Regulatory and Compliance Services
14.5.4.1.3.1.Regulatory Consulting

14.5.4.1.3.2.Quality Assurance and Control

14.5.4.1.3.3.Validation Services

14.5.4.1.4.Technology Transfer Services

14.5.4.1.5.Others

14.5.4.2.Kuwait CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.4.2.1.Oncology

14.5.4.2.2.Neurology

14.5.4.2.3.Cardiovascular

14.5.4.2.4.Infectious Diseases

14.5.4.2.5.Autoimmune Disorders

14.5.4.2.6.Others

14.5.4.3.Kuwait CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
14.5.4.3.1.Pharmaceuticals

14.5.4.3.2.Biotechnology

14.5.4.3.3.Medical Devices

14.5.4.3.4.Others

14.5.5.South Africa
14.5.5.1.South Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
14.5.5.1.1.Development Services
14.5.5.1.1.1.Formulation Development

14.5.5.1.1.2.Process Development

14.5.5.1.1.3.Analytical Development

14.5.5.1.1.4.Preclinical and Clinical Manufacturing

14.5.5.1.2.Manufacturing Services
14.5.5.1.2.1.API Manufacturing

14.5.5.1.2.2.Drug Product Manufacturing

14.5.5.1.2.3.Biologics Manufacturing

14.5.5.1.2.4.Medical Device Manufacturing

14.5.5.1.2.5.Packaging and Labeling

14.5.5.1.2.6.Supply Chain Management

14.5.5.1.3.Regulatory and Compliance Services
14.5.5.1.3.1.Regulatory Consulting

14.5.5.1.3.2.Quality Assurance and Control

14.5.5.1.3.3.Validation Services

14.5.5.1.4.Technology Transfer Services

14.5.5.1.5.Others

14.5.5.2.South Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.5.2.1.Oncology

14.5.5.2.2.Neurology

14.5.5.2.3.Cardiovascular

14.5.5.2.4.Infectious Diseases

14.5.5.2.5.Autoimmune Disorders

14.5.5.2.6.Others

14.5.5.3.South Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
14.5.5.3.1.Pharmaceuticals

14.5.5.3.2.Biotechnology

14.5.5.3.3.Medical Devices

14.5.5.3.4.Others

14.5.6.Rest of Middle East & Africa
14.5.6.1.Rest of Middle East & Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
14.5.6.1.1.Development Services
14.5.6.1.1.1.Formulation Development

14.5.6.1.1.2.Process Development

14.5.6.1.1.3.Analytical Development

14.5.6.1.1.4.Preclinical and Clinical Manufacturing

14.5.6.1.2.Manufacturing Services
14.5.6.1.2.1.API Manufacturing

14.5.6.1.2.2.Drug Product Manufacturing

14.5.6.1.2.3.Biologics Manufacturing

14.5.6.1.2.4.Medical Device Manufacturing

14.5.6.1.2.5.Packaging and Labeling

14.5.6.1.2.6.Supply Chain Management

14.5.6.1.3.Regulatory and Compliance Services
14.5.6.1.3.1.Regulatory Consulting

14.5.6.1.3.2.Quality Assurance and Control

14.5.6.1.3.3.Validation Services

14.5.6.1.4.Technology Transfer Services

14.5.6.1.5.Others

14.5.6.2.Rest of Middle East & Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
14.5.6.2.1.Oncology

14.5.6.2.2.Neurology

14.5.6.2.3.Cardiovascular

14.5.6.2.4.Infectious Diseases

14.5.6.2.5.Autoimmune Disorders

14.5.6.2.6.Others

14.5.6.3.Rest of Middle East & Africa CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
14.5.6.3.1.Pharmaceuticals

14.5.6.3.2.Biotechnology

14.5.6.3.3.Medical Devices

14.5.6.3.4.Others

14.6.Key Segment for Channeling Investments
14.6.1.By Country

14.6.2.By Service Type

14.6.3.By Therapeutic Area

14.6.4.By End Use Industry

15.Latin America CMO/CDMO Market Analysis and Forecasts, 2024 – 2034
15.1.Overview
15.1.1.Latin America CMO/CDMO Market Revenue (US$ Mn)

15.2.Latin America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
15.2.1.Development Services
15.2.1.1.Formulation Development

15.2.1.2.Process Development

15.2.1.3.Analytical Development

15.2.1.4.Preclinical and Clinical Manufacturing

15.2.2.Manufacturing Services
15.2.2.1.API Manufacturing

15.2.2.2.Drug Product Manufacturing

15.2.2.3.Biologics Manufacturing

15.2.2.4.Medical Device Manufacturing

15.2.2.5.Packaging and Labeling

15.2.2.6.Supply Chain Management

15.2.3.Regulatory and Compliance Services
15.2.3.1.Regulatory Consulting

15.2.3.2.Quality Assurance and Control

15.2.3.3.Validation Services

15.2.4.Technology Transfer Services

15.2.5.Others

15.3.Latin America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.3.1.Oncology

15.3.2.Neurology

15.3.3.Cardiovascular

15.3.4.Infectious Diseases

15.3.5.Autoimmune Disorders

15.3.6.Others

15.4.Latin America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
15.4.1.Pharmaceuticals

15.4.2.Biotechnology

15.4.3.Medical Devices

15.4.4.Others

15.5.Latin America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1.Brazil
15.5.1.1.Brazil CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
15.5.1.1.1.Development Services
15.5.1.1.1.1.Formulation Development

15.5.1.1.1.2.Process Development

15.5.1.1.1.3.Analytical Development

15.5.1.1.1.4.Preclinical and Clinical Manufacturing

15.5.1.1.2.Manufacturing Services
15.5.1.1.2.1.API Manufacturing

15.5.1.1.2.2.Drug Product Manufacturing

15.5.1.1.2.3.Biologics Manufacturing

15.5.1.1.2.4.Medical Device Manufacturing

15.5.1.1.2.5.Packaging and Labeling

15.5.1.1.2.6.Supply Chain Management

15.5.1.1.3.Regulatory and Compliance Services
15.5.1.1.3.1.Regulatory Consulting

15.5.1.1.3.2.Quality Assurance and Control

15.5.1.1.3.3.Validation Services

15.5.1.1.4.Technology Transfer Services

15.5.1.1.5.Others

15.5.1.2.Brazil CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.5.1.2.1.Oncology

15.5.1.2.2.Neurology

15.5.1.2.3.Cardiovascular

15.5.1.2.4.Infectious Diseases

15.5.1.2.5.Autoimmune Disorders

15.5.1.2.6.Others

15.5.1.3.Brazil CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
15.5.1.3.1.Pharmaceuticals

15.5.1.3.2.Biotechnology

15.5.1.3.3.Medical Devices

15.5.1.3.4.Others

15.5.2.Argentina
15.5.2.1.Argentina CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
15.5.2.1.1.Development Services
15.5.2.1.1.1.Formulation Development

15.5.2.1.1.2.Process Development

15.5.2.1.1.3.Analytical Development

15.5.2.1.1.4.Preclinical and Clinical Manufacturing

15.5.2.1.2.Manufacturing Services
15.5.2.1.2.1.API Manufacturing

15.5.2.1.2.2.Drug Product Manufacturing

15.5.2.1.2.3.Biologics Manufacturing

15.5.2.1.2.4.Medical Device Manufacturing

15.5.2.1.2.5.Packaging and Labeling

15.5.2.1.2.6.Supply Chain Management

15.5.2.1.3.Regulatory and Compliance Services
15.5.2.1.3.1.Regulatory Consulting

15.5.2.1.3.2.Quality Assurance and Control

15.5.2.1.3.3.Validation Services

15.5.2.1.4.Technology Transfer Services

15.5.2.1.5.Others

15.5.2.2.Argentina CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.5.2.2.1.Oncology

15.5.2.2.2.Neurology

15.5.2.2.3.Cardiovascular

15.5.2.2.4.Infectious Diseases

15.5.2.2.5.Autoimmune Disorders

15.5.2.2.6.Others

15.5.2.3.Argentina CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
15.5.2.3.1.Pharmaceuticals

15.5.2.3.2.Biotechnology

15.5.2.3.3.Medical Devices

15.5.2.3.4.Others

15.5.3.Rest of Latin America
15.5.3.1.Rest of Latin America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Service Type
15.5.3.1.1.Development Services
15.5.3.1.1.1.Formulation Development

15.5.3.1.1.2.Process Development

15.5.3.1.1.3.Analytical Development

15.5.3.1.1.4.Preclinical and Clinical Manufacturing

15.5.3.1.2.Manufacturing Services
15.5.3.1.2.1.API Manufacturing

15.5.3.1.2.2.Drug Product Manufacturing

15.5.3.1.2.3.Biologics Manufacturing

15.5.3.1.2.4.Medical Device Manufacturing

15.5.3.1.2.5.Packaging and Labeling

15.5.3.1.2.6.Supply Chain Management

15.5.3.1.3.Regulatory and Compliance Services
15.5.3.1.3.1.Regulatory Consulting

15.5.3.1.3.2.Quality Assurance and Control

15.5.3.1.3.3.Validation Services

15.5.3.1.4.Technology Transfer Services

15.5.3.1.5.Others

15.5.3.2.Rest of Latin America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By Therapeutic Area
15.5.3.2.1.Oncology

15.5.3.2.2.Neurology

15.5.3.2.3.Cardiovascular

15.5.3.2.4.Infectious Diseases

15.5.3.2.5.Autoimmune Disorders

15.5.3.2.6.Others

15.5.3.3.Rest of Latin America CMO/CDMO Market Revenue (US$ Mn) and Forecasts, By End Use Industry
15.5.3.3.1.Pharmaceuticals

15.5.3.3.2.Biotechnology

15.5.3.3.3.Medical Devices

15.5.3.3.4.Others

15.6.Key Segment for Channeling Investments
15.6.1.By Country

15.6.2.By Service Type

15.6.3.By Therapeutic Area

15.6.4.By End Use Industry

16.Competitive Benchmarking
16.1.Brand Benchmarking

16.2.Market Share Analysis, 2023

16.3.Global Presence and Growth Strategies
16.3.1.Mergers and Acquisitions

16.3.2.Product Launches

16.3.3.Investments Trends

16.3.4.R&D Initiatives

17.Player Profiles
17.1.AXXELENT
17.1.1.Company Details

17.1.2.Company Overview

17.1.3.Product Offerings

17.1.4.Key Developments

17.1.5.Financial Analysis

17.1.6.SWOT Analysis

17.1.7.Business Strategies

17.2.BDR Pharmaceuticals Internationals Pvt. Ltd.
17.2.1.Company Details

17.2.2.Company Overview

17.2.3.Product Offerings

17.2.4.Key Developments

17.2.5.Financial Analysis

17.2.6.SWOT Analysis

17.2.7.Business Strategies

17.3.CoreRx
17.3.1.Company Details

17.3.2.Company Overview

17.3.3.Product Offerings

17.3.4.Key Developments

17.3.5.Financial Analysis

17.3.6.SWOT Analysis

17.3.7.Business Strategies

17.4.Eurofins Scientific
17.4.1.Company Details

17.4.2.Company Overview

17.4.3.Product Offerings

17.4.4.Key Developments

17.4.5.Financial Analysis

17.4.6.SWOT Analysis

17.4.7.Business Strategies

17.5.HIKAL Ltd.
17.5.1.Company Details

17.5.2.Company Overview

17.5.3.Product Offerings

17.5.4.Key Developments

17.5.5.Financial Analysis

17.5.6.SWOT Analysis

17.5.7.Business Strategies

17.6.Idifarma
17.6.1.Company Details

17.6.2.Company Overview

17.6.3.Product Offerings

17.6.4.Key Developments

17.6.5.Financial Analysis

17.6.6.SWOT Analysis

17.6.7.Business Strategies

17.7.KBI Biopharma.
17.7.1.Company Details

17.7.2.Company Overview

17.7.3.Product Offerings

17.7.4.Key Developments

17.7.5.Financial Analysis

17.7.6.SWOT Analysis

17.7.7.Business Strategies

17.8.Laurus Synthesis
17.8.1.Company Details

17.8.2.Company Overview

17.8.3.Product Offerings

17.8.4.Key Developments

17.8.5.Financial Analysis

17.8.6.SWOT Analysis

17.8.7.Business Strategies

17.9.Lonza
17.9.1.Company Details

17.9.2.Company Overview

17.9.3.Product Offerings

17.9.4.Key Developments

17.9.5.Financial Analysis

17.9.6.SWOT Analysis

17.9.7.Business Strategies

17.10.mAbxience
17.10.1.Company Details

17.10.2.Company Overview

17.10.3.Product Offerings

17.10.4.Key Developments

17.10.5.Financial Analysis

17.10.6.SWOT Analysis

17.10.7.Business Strategies

17.11.Piramal Pharma Solutions
17.11.1.Company Details

17.11.2.Company Overview

17.11.3.Product Offerings

17.11.4.Key Developments

17.11.5.Financial Analysis

17.11.6.SWOT Analysis

17.11.7.Business Strategies

17.12.QuayPharma
17.12.1.Company Details

17.12.2.Company Overview

17.12.3.Product Offerings

17.12.4.Key Developments

17.12.5.Financial Analysis

17.12.6.SWOT Analysis

17.12.7.Business Strategies

17.13.Sai Life Sciences
17.13.1.Company Details

17.13.2.Company Overview

17.13.3.Product Offerings

17.13.4.Key Developments

17.13.5.Financial Analysis

17.13.6.SWOT Analysis

17.13.7.Business Strategies

17.14.Samsung Biologics
17.14.1.Company Details

17.14.2.Company Overview

17.14.3.Product Offerings

17.14.4.Key Developments

17.14.5.Financial Analysis

17.14.6.SWOT Analysis

17.14.7.Business Strategies

17.15.Other Industry Participants

18.Key Findings

.

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

.

**Exclusive for Multi-User and Enterprise User.

Global CMO/CDMO Market

By Service Type

  • Development Services
    • Formulation Development
    • Process Development
    • Analytical Development
    • Preclinical and Clinical Manufacturing
  • Manufacturing Services
    • API Manufacturing
    • Drug Product Manufacturing
    • Biologics Manufacturing
    • Medical Device Manufacturing
    • Packaging and Labelling
    • Supply Chain Management
  • Regulatory and Compliance Services
    • Regulatory Consulting
    • Quality Assurance and Control
    • Validation Services
  • Technology Transfer Services
  • Others

By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiovascular
  • Infectious Diseases
  • Autoimmune Disorders
  • Others

By End Use Industry

  • Pharmaceuticals
  • Biotechnology
  • Medical Devices
  • Others

By Region

  • North America (U.S., Canada, Mexico, Rest of North America)
  • Europe (France, The UK, Spain, Germany, Italy, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway), Benelux Union (Belgium, The Netherlands, Luxembourg), Rest of Europe)
  • Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Rest of Asia Pacific)
  • Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa)
  • Latin America (Brazil, Argentina, Rest of Latin America)

The Niche Research approach encompasses both primary and secondary research methods to provide comprehensive insights. While primary research is the cornerstone of our studies, we also incorporate secondary research sources such as company annual reports, premium industry databases, press releases, industry journals, and white papers.

Within our primary research, we actively engage with various industry stakeholders, conducting paid interviews and surveys. Our meticulous analysis extends to every market participant in major countries, allowing us to thoroughly examine their portfolios, calculate market shares, and segment revenues.

Our data collection primarily focuses on individual countries within our research scope, enabling us to estimate regional market sizes. Typically, we employ a bottom-up approach, meticulously tracking trends in different countries. We analyze growth drivers, constraints, technological innovations, and opportunities for each country, ultimately arriving at regional figures.Our process begins by examining the growth prospects of each country. Building upon these insights, we project growth and trends for the entire region. Finally, we utilize our proprietary model to refine estimations and forecasts.

Our data validation standards are integral to ensuring the reliability and accuracy of our research findings. Here’s a breakdown of our data validation processes and the stakeholders we engage with during our primary research:

  • Supply Side Analysis: We initiate a supply side analysis by directly contacting market participants, through telephonic interviews and questionnaires containing both open-ended and close-ended questions. We gather information on their portfolios, segment revenues, developments, and growth strategies.
  • Demand Side Analysis: To gain insights into adoption trends and consumer preferences, we reach out to target customers and users (non-vendors). This information forms a vital part of the qualitative analysis section of our reports, covering market dynamics, adoption trends, consumer behavior, spending patterns, and other related aspects.
  • Consultant Insights: We tap into the expertise of our partner consultants from around the world to obtain their unique viewpoints and perspectives. Their insights contribute to a well-rounded understanding of the markets under investigation.
  • In-House Validation: To ensure data accuracy and reliability, we conduct cross-validation of data points and information through our in-house team of consultants and utilize advanced data modeling tools for thorough verification.

The forecasts we provide are based on a comprehensive assessment of various factors, including:

  • Market Trends and Past Performance (Last Five Years): We accurately analyze market trends and performance data from preceding five years to identify historical patterns and understand the market’s evolution.
  • Historical Performance and Growth of Market Participants: We assess the historical performance and growth trajectories of key market participants. This analysis provides insights into the competitive landscape and individual company strategies.
  • Market Determinants Impact Analysis (Next Eight Years): We conduct a rigorous analysis of the factors that are projected to influence the market over the next eight years. This includes assessing both internal and external determinants that can shape market dynamics.
  • Drivers and Challenges for the Forecast Period:Identify the factors expected to drive market growth during the forecast period, as well as the challenges that the industry may face. This analysis aids in deriving an accurate growth rate projection.
  • New Acquisitions, Collaborations, or Partnerships: We keep a close watch on any new acquisitions, collaborations, or partnerships within the industry. These developments can have a significant impact on market dynamics and competitiveness.
  • Macro and Micro Factors Analysis:A thorough examination of both macro-level factors (e.g., economic trends, regulatory changes) and micro-level factors (e.g., technological advancements, consumer preferences) that may influence the market during the forecast period.
  • End-User Sentiment Analysis: To understand the market from the end-user perspective, we conduct sentiment analysis. This involves assessing the sentiment, preferences, and feedback of the end-users, which can provide valuable insights into market trends.
  • Perspective of Primary Participants: Insights gathered directly from primary research participants play a crucial role in shaping our forecasts. Their perspectives and experiences provide valuable qualitative data.
  • Year-on-Year Growth Trend: We utilize a year-on-year growth trend based on historical market growth and expected future trends. This helps in formulating our growth projections, aligning them with the market’s historical performance.

Research process adopted by TNR involves multiple stages, including data collection, validation, quality checks, and presentation. It’s crucial that the data and information we provide add value to your existing market understanding and expertise. We have also established partnerships with business consulting, research, and survey organizations across regions and globally to collaborate on regional analysis and data validation, ensuring the highest level of accuracy and reliability in our reports.

 

 

Procure Comprehensive Study of

Global CMO/CDMO Market

Online Only

  • Online Access
  • Read Only File
  • Validity 3 Months
  • Print, Copy, Paste & Download
  • PPT, Excel
  • Cost-Free Report in the Next Update
$3300
Buy Now

Single User

  • Access to One User on One System
  • Read Only File
  • Validity 6 Months
  • Limited Print,Copy, Paste
  • PPT, Excel
  • Cost-Free Report in the Next Update
$4200
Buy Now

Multi User

  • Access to Fiver Users
  • PDF File
  • Validity 1 Year
  • Upto FivePrints
  • Cost-Free Report in the Next Update
  • PPT, Excel
$6000
Buy Now

Enterprise User

  • Access to Unlimited Users
  • PDF, PPT, Excel
  • Unlimited Validity, Prints&Downloads
  • 1 Hour Cost-Free & Dedicated Analyst Support
  • 10% Cost-Free Customization
  • Cost-Free Report Update Twice in a Year
  • Recommendations for Business Strategies
  • Authorization to Quote TNR, The Niche Research
$7300
Buy Now

Library Access

  • Online Access to Content Publications
  • Access Player Profiles Online
  • Get Immediate Access to Newly Added Content
  • Acquire 12 PDF Downloads
  • Acquire 5 Excel Data Sets
  • Gain Access to 290+ PDFs of Company Profiles
  • Round-the-clock Email and Phone Assistance
  • Dashboard Usage and Trends
  • Renewal & Upgrade Assistance
  • Assessing Customization Options and Alerts for New Reports
$10788
Buy Now
*Taxes/Fees, if applicable will be added during checkout. All prices in USD

Why TNR The Niche Research?

  • Unwavering Commitment to Excellence

  • Veteran Team of Researchers

  • Accurate and Timely Insights

  • Ethical Practices and Customized Service

  • Uninterrupted Availability Around the Clock

Scroll to Top